
Office of Communications
and Public Liaison (OCPL)
Building 31, Room 5C27
31 Center Drive, MSC 2292
Bethesda, MD 20892
Phone: 301-496-1752
nianews3@mail.nih.gov
Two international teams of researchers, with NIH scientists and support, have separately identified a rare variation in the TREM2 gene as a moderate risk factor for late-onset Alzheimer’s disease. TREM2 is a gene involved in...
An international team of researchers has found that the vitamin D receptor gene (VDR), which senses and communicates the presence of vitamin D to the body, influences the chance that people with vitamin D deficiency develop negative health...
Standardized neurological, behavioral measures to aid clinical research Unveiled in September 2012, the NIH Toolbox for Assessment of Behavioral and Neurological Function provides common, standardized measurements that will make it...
A team of NIH-supported researchers has confirmed a link between age-related hearing loss and a gene producing a key protein in the inner ear. The findings reinforce observations in older people that genetics and environment interact,...
NIH, Alzheimer’s Association invite research funders to participate A new, publicly available database is seeking to capture the full spectrum of current Alzheimer’s disease research investments and resources—both in...
The NIA’s GEMSSTAR – Grants for Early Medical/Surgical Specialists' Transition to Aging Research – program is winning rave reviews for enabling physicians just starting out in their careers to connect their specialty...
Epigenetics, the study of how the environment modifies the way the human gene is expressed, is an emerging frontier in science. Diet and exposure to environmental chemicals, among other factors, can cause epigenetic changes that may turn...
Posiphen, a drug candidate designed and developed by researchers in the NIA’s Intramural Research Program, has been shown in three small, early studies to be well-tolerated and to reduce the generation of amyloid and tau protein...
Numerous clinical trials and studies are currently recruiting participants with and without Alzheimer's disease, mild cognitive impairment or related dementias. NIA’s Alzheimer’s Disease Education and Referral (ADEAR)...
Throughout history, the natural world has served as a rich resource for compounds to treat human disease. For example, clay tablets from Mesopotamia dating from 2600 B.C.—humanity’s earliest written records—describe the...